Turning stats into outcomes
November 09, 2012
Shares in Novo Nordisk have soared this morning after an FDA panel recommended approval of Tresiba and Ryzodeq, despite expressing concerns over possible cardiovascular risk of the ultra long-acting insulins
November 01, 2012
Novo Nordisk has posted another healthy set of figures for the third quarter, helped by strong sales of diabetes drug Victoza and its modern insulins
October 22, 2012
Recommendations from EMA advisors include rejecting Lundbeck’s Acrescent for Alzheimer’s disease, and approving Novo Nordisk's diabetes drugs Tresiba and Ryzodeg.
PharmaTimes 2013 Copyright | RSS Feed Subscriptions